# A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

> **NCT05890729** · PHASE1,PHASE2 · RECRUITING · sponsor: **Xentria, Inc.** · enrollment: 94 (estimated)

## Conditions studied

- Pulmonary Sarcoidosis

## Interventions

- **DRUG:** XTMAB-16 or Placebo

## Key facts

- **NCT ID:** NCT05890729
- **Lead sponsor:** Xentria, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-10
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05890729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05890729, "A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05890729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*